Calvin Knowlton, BScPharm, MDiv, PhD, chief executive officer and founder of Tabula Rasa HealthCare, discusses who benefits most from the Enhanced Medication Therapy Management Model, how advances in technology have enhanced these services, and what best practices have been identified.
Calvin Knowlton, BScPharm, MDiv, PhD, chief executive officer and founder of Tabula Rasa HealthCare, discusses who benefits most from the Enhanced Medication Therapy Management Model, how advances in technology have enhanced these services, and what best practices have been identified.
Transcript
Last year CMMI introduced the Enhanced Medication Therapy Management Model. Who can benefit most from this model?
Enhanced Medication Therapy Management really targets people that are at high risk for adverse drug events, and who could that be? It’s mostly elderly people. The government has a study out from the CDC that shows that 50% of the elderly are taking 5 or more medications a day, and they have about a 50% chance of an adverse drug event once a year. When you get up to 10 medications a day, it’s about an 82% chance of an adverse drug event once a year. So, that’s the people we target. The folks that are taking multiple medications, they’re at high risk for an adverse drug event. They benefit the most.
How have advances in technology impacted eMTM services?
Part of the reason we can do this now is because of the advancement of technology, the speed of which in half a second we can take 10 or 15 drugs and instantaneously give the user information. We can work in the cloud, so it can be used internationally, which it is. So, the technology is really what has supported this.
Plus, because of technology, we’re able to go back to the basics of science that we learned in pharmacy school but were not able to apply at the bench because it was just too complicated and too difficult. But, now with the technology, we can do instantaneous things we couldn’t do even 5 years ago.
What best practices have you identified in using eMTM to improve population health and patient outcomes?
One of the best practices is that we’ve taken all this information that I explained, the multicomponents of the simultaneous drug interaction system, and boil it into a risk score from 0-50, 50 being terrible and 0 being wonderful. So, we can see right away a patient’s risk score, and we say just like you know what your FICO credit score is for credit risk, well maybe in a few years we’ll know what our medication risk score is for our mother’s medications.
So, it’s a score that can be carried and be compared from 1 person to another, and also the good news is it’s a score that can be lowered. There’s things you can do to change the regimen or change the time of day when they take the medicine, So, if this one gets into those parking spaces first, we’ll take this one first and we’ll take this one at supper, for example, when it’s clear, instead of taking them all at once. So, the risk score has been very helpful in comparison and in encouraging people that if we make some changes in the regimen, then you’re going to have less risk for an adverse drug event.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More